U
Uberbert
In searching this forum, I found threads on the “what” and “how” of design transfer but not so much on when. Conversations with quality engineers have suggested my perspective is off base.
As I read the standard and guidance, design transfer should occur before design verification and certainly before design validation. As a design engineer, 14 years ago I helped set up a quality system at a design engineering firm. We had a design transfer process and form that we used almost every time we released drawings to make an injection mold. I am helping set up another system again and wanted to confirm that strategy.
I think my argument can be summed up this way.
1. the definition of design validation indicates that there are device specifications to validate, therefore device specifications come before validation
2. the output of design transfer is production specifications, therefore design transfer comes before production specifications
3. Given 1 and 2 and assuming “device specifications" and "production specifications" are equivalent, design transfer comes before validation.
Other perspectives I have seen are (1) that design transfer occurs after design validation is complete and (2) is intended to ensure that the DMR is complete and adequate. My argument above refutes the (1) and regarding (2), neither the standard nor the guidance say anything about DMR in the design transfer section.
Finally, assuming design transfer occurs before design validation, I think the FDA chose poorly in listing it in the standard after design verification and design validation.
If I am off base or missing something, please explain.
As I read the standard and guidance, design transfer should occur before design verification and certainly before design validation. As a design engineer, 14 years ago I helped set up a quality system at a design engineering firm. We had a design transfer process and form that we used almost every time we released drawings to make an injection mold. I am helping set up another system again and wanted to confirm that strategy.
I think my argument can be summed up this way.
1. the definition of design validation indicates that there are device specifications to validate, therefore device specifications come before validation
2. the output of design transfer is production specifications, therefore design transfer comes before production specifications
3. Given 1 and 2 and assuming “device specifications" and "production specifications" are equivalent, design transfer comes before validation.
Other perspectives I have seen are (1) that design transfer occurs after design validation is complete and (2) is intended to ensure that the DMR is complete and adequate. My argument above refutes the (1) and regarding (2), neither the standard nor the guidance say anything about DMR in the design transfer section.
Finally, assuming design transfer occurs before design validation, I think the FDA chose poorly in listing it in the standard after design verification and design validation.
If I am off base or missing something, please explain.